ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Geropharm and Hanmi Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GeropharmHanmi Pharmaceutical
studies on the registry23191
open to participants now012
phase 3 studies under way13
reach primary completion within a year08
programswith a study of their own in two years112

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGeropharmHanmi Pharmaceutical
Phase 100%

Hanmi Pharmaceutical: 4 of its 12 programs at phase 1

  1. HIP2503phase 1
  2. HM17321phase 1
  3. IL-2 Mutein/Fc Fusion Protein HM16390phase 1
  4. RLD2606phase 1
33%
Phase 200%

Hanmi Pharmaceutical: 3 of its 12 programs at phase 2

  1. belvarafenibphase 2
  2. HM15275phase 2
  3. cobimetinibphase 2
25%
Phase 3

Geropharm: 1 of its 1 programs at phase 3

  1. insulin glulisinephase 3
100%

Hanmi Pharmaceutical: 5 of its 12 programs at phase 3

  1. efpeglenatidephase 3
  2. HCP1306phase 3
  3. HCP1803-4phase 3
  4. hip2602phase 3
  5. hpp2602-2phase 3
42%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Geropharm0 readouts · 0 phase 3············
Hanmi Pharmaceutical6 readouts · 3 phase 3··

Hanmi Pharmaceutical, Jan ’27: 1 program whose next study reaches primary completion

  1. HM15275phase 2 · Jan 0 · NCT07205900

Hanmi Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. RLD2606phase 1 · Feb 5 · NCT07939087

Hanmi Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. HM17321phase 1 · Mar 0 · NCT07219589
·····

Hanmi Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. hip2602phase 3 · Sep 0 · NCT07899073
  2. hpp2602-2phase 3 · Sep 0 · NCT07899073

Hanmi Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HCP1803-4phase 3 · Oct 30 · NCT07660796
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Geropharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Hanmi Pharmaceutical

New programs 3

  • RLD2606phase 1 · first study · Nov 10
  • hip2602phase 3 · first study · Oct 20 · Erectile Dysfunction
  • hpp2602-2phase 3 · first study · Oct 20 · Erectile Dysfunction

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionGeropharmHanmi Pharmaceutical
Diabetes Mellitus, Type 2both · compare here

Geropharm in Diabetes Mellitus, Type 2: 1 program

  1. insulin glulisinephase 3

Their studies: Geropharm’s studies of Diabetes Mellitus, Type 2 in search

Hanmi Pharmaceutical in Diabetes Mellitus, Type 2: 2 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Diabetes Mellitusboth · compare here

Geropharm in Diabetes Mellitus: 1 program

  1. insulin glulisinephase 3

Their studies: Geropharm’s studies of Diabetes Mellitus in search

Hanmi Pharmaceutical in Diabetes Mellitus: 1 program

  1. efpeglenatidephase 3

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Geropharm 1 of 1 · Hanmi Pharmaceutical 5 of 12 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.